Initial burden of disease estimates for South Africa, 2000.

To estimate the burden of disease of Guillain-Barré syndrome (GBS) in Brazil in 2014, 1year before the Zika virus epidemic, and in 2015 and 2016 during the epidemic. The burden of disease of GBS was estimated using the summary measure of population health: Disability Adjusted Life Years (DALY), that combines both mortality (Years of Life Lost YLLs) and morbidity (Years Lived with Disability) components. The study population was composed of GBS hospitalised cases and deaths from the information systems of the Brazilian Unified Health System. The GBS incidence rate in 2014, 2015 and 2016 was 0.74, 0.96, 1.02/100000 respectively, and the mortality rate in the same period was 0.08, 0.009 and 0.11/100000 habitants. The DALYs calculated using the point estimate of GBS disability weight and its values of the confidence interval (0.198 and 0.414) were 5725.90 (5711.79-5742.89) in 2014, 6054.61 (6035.57-6077.54) in 2015 and 7588.49 (7570.20-7610.51) in 2016. The DALYs were high among the male population and in age groups between 20 and 50years. The increase in DALYs in the years 2015 and 2016 compared to 2014 probably resulted from the introduction of ZIKV in Brazil, reinforcing the importance of investments in the prevention of ZIKV infection and in the care of GBS patients.

Background Multiple sclerosis (MS) is a chronic autoimmune and inflammatory disease of the central nervous system leading to progressive disability. Due to its long-term impact on individuals and the need for continuous care, MS poses considerable challenges for healthcare systems. Accurate burden estimates are crucial for evidence-based decision-making and resource allocation. As part of the Belgian national burden of disease study (BeBOD), this study aims to estimate the burden of MS in Belgium using nationally representative data. Methods We estimated the burden of MS in Belgium in terms of prevalence, deaths, years lived with disability (YLD), years of life lost (YLL), and disability-adjusted life years (DALY). In the absence of a comprehensive national prevalence dataset, we evaluated local and national data sources based on their specificity and sensitivity. Prevalence estimates were combined with disability weights to calculate YLDs. YLLs were computed using the most recent Global Burden of Disease (GBD) 2019 reference life table and the number of MS-related deaths (ICD-10 code G35) from Statbel, the Belgian statistical office. Results A sentinel network of general practitioners was identified as the most suitable data source, estimating MS prevalence at 0.19%. The non-fatal burden of MS was 79 YLD per 100,000, and YLL was 48 per 100,000. We estimated 14,732 DALYs caused by MS in 2022, of which 62% were due to YLD and 38% due to YLL. Our MS burden estimates for Belgium were higher than those of GBD, likely because their Belgian data rely on a single, older study from the early 1990s. Conclusions In Belgium, MS accounted for an estimated 14,732 DALYs in 2022, with a slightly higher contribution from morbidity than mortality. These findings underline the impact of MS on both quality of life and life expectancy. Using locally sourced data offers a more context-specific view than global estimates and can support evidence-based planning and resource allocation. Key messages • MS causes a substantial burden through both disability and premature mortality, reflecting its chronic and progressive nature. • National MS burden estimates support informed health policy and resource planning.

Today, several countries are conducting national burden of disease (BOD) studies, calculating Disability-Adjusted Life Years (DALYs) for a variety of diseases, injuries and risk factors. The DALY metric is composed of a morbidity component, the Years Lived with Disability (YLDs), and a mortality component, the Years of Life Lost (YLLs). The calculation of YLLs typically starts from national cause of death data, which are coded using the International Statistical Classification of Diseases and Related Health Problems (ICD). National BOD studies however often follow (a modified version of) the cause hierarchy of the Global Burden of Disease (GBD) study, which applies coarser categories, and does not contain unknown or ill-defined causes. This implies that not all ICD codes can be mapped to one specific BOD cause, giving rise to so-called “ill-defined” or “garbage” codes. To include all deaths in a national BOD study, it is therefore necessary to redistribute the ill-defined deaths to specific BOD causes. Several methodological approaches exist for redistribution of ill-defined deaths, ranging from the use of fixed redistribution proportions to advanced redistribution algorithms based on multiple cause of death data. The choice of the methodology needs to depend on the nature of the available cause of death data, and as a consequence, methodologies are typically tailored to the specific data at hand. The absence of a single best methodology, and the methodological heterogeneity across applications, has made redistribution of ill-defined deaths into a methodological conundrum. This skills building workshop will present the redistribution methods applied in different national burden of disease studies, including a discussion of their strengths and weaknesses. By providing a step-by-step presentation of how the methods have been applied, attendees will gain unique insights in the different redistribution methods currently applied.Key messages• Redistribution of ill-defined deaths is an essential part of national burden of disease studies, but is methodologically challenging.• Attendees will receive an overview of the redistribution methods applied in different national burden of disease studies, including a discussion of their strengths and weaknesses.

Inflammatory bowel disease (IBD) comprises digestive disorders resulting from non-infectious inflammation of the colon and gastrointestinal tract. With its global prevalence on the rise, IBD poses significant challenges to healthcare systems. There is a need for more accurate disease burden estimates to guide decision-making processes within the health sector. As a part of the Belgian national burden of disease study (BeBOD), this study aims to estimate the burden of IBD in Belgium based on locally available data. We estimated the Belgian IBD burden in 2020 in terms of mortality, prevalence, years of life lost (YLLs) due to premature death, years lived with disability (YLDs), and disability-adjusted life years (DALYs). As there is no single comprehensive data source on prevalence of IBD in Belgium, a critical appraisal of existing local and national data sources was conducted. Prevalence data were combined with disability weights to yield YLDs. YLLs were calculated using the most recent Global Burden of Disease (GBD) 2019 reference life table and the number of deaths caused by non-infective IBD (ICD-10 K50-52). Cause of death data were extracted from Statbel, the Belgian statistical office. The best available data source to estimate the IBD prevalence in Belgium was a widespread network of general practitioners. The prevalence of IBD was 1.5% in 2020. The prevalence-based YLD for IBD was 220 YLDs per 100 000, while the YLL rate was 11.5 per 100 000. We estimated 26 276 DALYs caused by IBD in 2020. Of the total DALYs caused by IBD, 5% were due to YLLs and 95% were due to YLDs. Our burden estimates for IBD in Belgium were however higher than those of the GBD study. IBD imposes a low fatal burden, whereas the burden of morbidity is more prominent. Our findings could be useful for policy makers to justify and prioritize resource allocation. Integrating the current research in BeBOD will allow monitoring the burden of IBD over time. Key messages • Inflammatory bowel disease is characterized by a substantial non-fatal burden due to chronic relapsing and persistent symptoms. • National inflammatory bowel disease burden estimates are useful to guide decision-making within the health sector.

BackgroundBurden of Disease (BoD) studies use disability-adjusted life years (DALYs) as a population health metric to quantify the years of life lost due to morbidity and premature mortality for diseases, injuries and risk factors occurring in a region or a country. Small countries usually face a number of challenges to conduct epidemiological studies, such as national BoD studies, due to the lack of specific expertise and resources or absence of adequate data. Considering Europe’s small countries of Cyprus, Iceland, Luxembourg, Malta and Montenegro, the aim was to assess whether the various national data sources identified are appropriate to perform national BoD studies.Main bodyThe five small countries have a well-established mortality registers following the ICD10 classification, which makes calculation of years of life lost (YLL) feasible. A number of health information data sources were identified in each country, which can provide prevalence data for the calculation of years lived with disability (YLD) for various conditions. These sources include disease-specific registers, hospital discharge data, primary health care data and epidemiological studies, provided by different organisations such as health directorates, institutes of public health, statistical offices and other bodies. Hence, DALYs can be estimated at a national level through the combination of the YLL and YLD information.On the other hand, small countries face unique challenges such as difficulty to ensure sample representativeness, variations in prevalence estimates especially for rarer diseases, existence of a substantial proportion of non-residents affiliated to healthcare systems and potential exclusion from some European or international initiatives.Recently established BoD networks may provide a platform for small countries to share experiences, expertise, and engage with countries and institutions that have long-standing experience with BoD assessment.ConclusionApart from mortality registries, adequate health data sources, notably for cancer, are potentially available at the small states to perform national BoD studies. Investing in sharing expert knowledge through engagement of researchers in BoD networks can enable the conduct of country specific BoD studies and the establishment of more accurate DALYs estimates. Such estimates can enable local policymakers to reflect on the relative burden of the different conditions that are contributing to morbidity and mortality at a country level.

Актуальность: Лейкемия — распространенное злокачественное новообразование, имеющее четыре основных подтипа и представляющее угрозу для здоровья человека. Понимание эпидемиологического статуса лейкемии и ее четырех основных подтипов во всем мире важно для выделения соответствующих ресурсов, руководства клинической практикой и необходимости проведения дальнейших исследований. Цель: Анализ данных глобального бремени лейкемии среди стран Центральной Азии за период с 2014 по 2019 годы. Материалы и методы:Проведен анализ основных показателей бремени лейкемии с использованием базы данных «Глобальное бремя болезней» (GBD 2019) за период с 2014–2019 гг. Мы рассчитали 3 вторичных показателя отношения лет жизни с поправкой на инвалидность (DALY) к распространенности, отношения распространенности к заболеваемости и отношения потерянных лет жизни (YLL) к количеству лет, прожитых с инвалидностью (YLD). Результаты: За период с 2014 по 2019 годы были зарегистрированы высокие показатели YLL, DALY среди таких стран как Грузия, Азербайджан и Армения. Касательно, показателя YLD наивысший показатель зарегистрирован в Российской Федерации. Также важно отметить, что в Республике Казахстан наблюдается тенденция ежегодного прироста показателя YLD. В то время как, по показателям YLL, DALYотмечена незначительная тенденция к снижению бремени лейкемии, по Республике Казахстан среднегодовые процентные изменения (AAPCs) варьировались от - 1.34% до -1.38% в период с 2014 - 2019 годы. Заключение: В период с 2014 по 2019 годы наблюдалось значительное снижение бремени лейкемией. Однако в 2019 году показатель YLD значительно увеличился в некоторых странах Центральной Азии, что позволяет предположить, что лейкемия может стать серьезной глобальной проблемой общественного здравоохранения. Introduction. Leukemia is a common malignancy that has four main subtypes and is a threat to human health. Understanding the epidemiological status of leukemia and its four main subtypes globally is important for allocating appropriate resources, guiding clinical practice, and furthering scientific research Objective: Analysis of data on the global burden of leukemia among the countries of Central Asia for the period from 2014 to 2019. Material and methods: An analysis of the main indicators of the burden of leukemia was carried out using the Global Burden of Disease database (GBD 2019) for the period from 2014–2019. We calculated 3 secondary measures of the ratio of disability-adjusted life years (DALY) to prevalence, the ratio of prevalence to incidence, and the ratio of years of life lost (YLL) to years lived with disability (YLD). Results: For the period from 2014 to 2019, high rates of YLL, DALY were registered among such countries as Georgia, Azerbaijan and Armenia. Regarding the YLD indicator, the highest indicator is registered in the Russian Federation. It is also important to note that in the Republic of Kazakhstan there is a trend of an annual increase in the YLD indicator. While there is a slight downward trend in the burden of leukemia as measured by YLL, DALY, the average annual percentage changes (AAPCs) ranged from -1.34% to 1.38% in the Republic of Kazakhstan between 2014 and 2019. Conclusion: Between 2014 and 2019, there was a significant decrease in the burden of leukemia. However, in 2019 YLD increased significantly in some Central Asian countries, suggesting that leukemia could become a major global public health problem. Кіріспе: Лейкемия – негізгі төрт түрі бар және адам денсаулығына қауіп төндіретін кең таралған қатерлі ісік. Әлем бойынша лейкемияның эпидемиологиялық мәртебесін және оның негізгі төрт түрін ұғыну тиісті ресурстарды бөлу, клиникалық тәжірибе басшылығы үшін және ары қарай зерттеу жүргізу қажеттілігі үшін маңызды. Мақсаты: Орта Азия елдері арасында 2014 және 2019 жыл аралығында лейкемияның жаһандық ауртпалығы деректерін талдау. Материалдар және әдістер: 2014-2019 ж. аралығында «Аурулардың жаһандық ауыртпалығы» (GBD 2019) деректер базасын пайдаланумен лейкемия ауыртпалығының негізгі көрсеткіштеріне талдау жүргізілді. Біз аурудың таралуына мүгедектіккебейімделген өмір жылы (DALY) қатынасы, аурудың таралуына қатынасы және мүгедектікпен сүрген өмір санына (YLD) жоғалтқан өмір жылдарының (YLL) қатынасы секілді 3 қайталанған көрсеткішті есептедік. Нәтижелерi: 2014 және2019 жыл аралығында жүргізілген зерттеу деректеріне сәйкес, Грузия, Әзірбайжан және Армения секілді елдер арасында YLL, DALY жоғары көрсеткіштері тіркелген. YLD көрсеткішіне қатысты ең жоғары көрсеткіш Ресей Федерациясында тіркелген. Сонымен қатар Қазақстан Республикасында YLD көрсеткішінің жыл сайын өсу тенденциясы байқалып жатқанын атап өткен маңызды. YLL, DALY көрсеткіштері бойынша лейкемия ауыртпалығы төмендеуінің елеусіз тенденциясы байқалады, Қазақстан Республикасында 2014-2019 жыл аралығында орташа жылдық пайыздық өзгерістер (AAPCs) - 1.34%-дан 1.38%-ға дейін өзгерді. Қорытындылар: 2014 және2019 жыл аралығында лейкемия ауыртпалығының едәуір төмендегені байқалды. Алайда2019 жылы YLD көрсеткіші Орта Азияның кейбір елдерінде едәуір ұлғайған, бұл лейкемияның қоғамдық денсаулық сақтау ұйымының маңызды жаһандық мәселесіне айналуы мүмкіндеген болжам жасауға мүмкіндік береді.

To estimate the magnitude and characteristics of the injury burden in South Africa within a global context. The Actuarial Society of South Africa demographic and AIDS model (ASSA 2002) - calibrated to survey, census and adjusted vital registration data - was used to calculate the total number of deaths in 2000. Causes of death were determined from the National Injury Mortality Surveillance System profile. Injury death rates and years of life lost (YLL) were estimated using the Global Burden of Disease methodology. National years lived with disability (YLDs) were calculated by applying a ratio between YLLs and YLDs found in a local injury data source, the Cape Metropole Study. Mortality and disability-adjusted life years' (DALYs) rates were compared with African and global estimates. Interpersonal violence dominated the South African injury profile with age-standardized mortality rates at seven times the global rate. Injuries were the second-leading cause of loss of healthy life, accounting for 14.3% of all DALYs in South Africa in 2000. Road traffic injuries (RTIs) are the leading cause of injury in most regions of the world but South Africa has exceedingly high numbers - double the global rate. Injuries are an important public health issue in South Africa. Social and economic determinants of violence, many a legacy of apartheid policies, must be addressed to reduce inequalities in society and build community cohesion. Multisectoral interventions to reduce traffic injuries are also needed. We highlight this heavy burden to stress the need for effective prevention programmes.

Objectives: To analyze the status quo and trends on the burden of cerebrovascular diseases between 1990 and 2016 in China. Methods: Morbidity mortality, years of life lost (YLL), years of lived with disability (YLD) and disability-adjusted life year (DALY) related to cerebrovascular diseases between 1990 and 2016, were collated and analyzed, according to the results of the Global Burden of Diseases Study 2016 (GBD 2016). Numbers on incidence and morbidity were used to assess the incidence of diseases, while the numbers of death and mortality were used to assess the death of diseases. Years of life lost due to premature death (YLL), years lost due to disability (YLD) and disability-adjusted life year (DALY) were used to assess the burden of diseases. Changing trend on the burden of cerebrovascular disease from 1990 to 2016 was also analyzed. Results: In 2016 and 1990, the numbers of new cases/morbidity and the number of deaths/mortality on cerebrovascular diseases in the country showed an upward trend. Rates regarding YLL and DALY on cerebrovascular diseases remained stable from 1990 to 2016, however, the YLD rate showed a slow upward trend. The changing rate of DALY was mainly influenced by YLL. Both DALY and YLL crude rates in males showed a slow upward trend, with the highest DALY rate appearing in the ≥70 age group. Disease burden on males was heavier than that of the females and in the 50-60 age group, which taking the largest proportion. As for the composition in DALY, YLL appearing much larger than YLD and slowly increasing. Analysis on the subtypes of diseases, proportions of YLL and DALY in hemorrhagic stroke were greater than that in ischemic stroke while the proportion of YLD in ischemic stroke was in the opposite. Conclusions: The burden of disease on cerebrovascular diseases remained heavy and the differences appeared in age, gender and subtypes of diseases. Our findings called for the adoption of measures including screening, intervention and rehabilitation to be taken on target populations, in order to reduce the burden on both individuals and the society.

South Korea has been measuring its own burden of disease since the early 2000s and has developed a methodology for its calculation. Since 2012, South Korea has been carrying out disease burden research through the Research and Development Project, supported by the Ministry of Health and Welfare. Because the Korean health insurance system covers the entire population of the country, the Korean National Burden of Disease (KNBD) study is based on individual claims data. Disease prevalence, incidence, and mortality rates, which are the epidemiologic indicators used to calculate burden of disease, are based on actual data, and the incidence-based approach is used for Years Lived with disability (YLD), Years of Life Lost (YLL), and Disability Adjusted Life Year (DALY). The KNBD study is conducted for 260 diseases and injuries and subdivided into sub-national levels. Disability weights (DW) are calculated to reflect the sociocultural characteristics of a disease. For cause-specific DWs, we conducted a self-administered web-based survey for medical doctors and students. Using a ranking method, we calculated cause-specific DWs. For this reason, KNBD study results cannot be directly compared with GBD results. The major findings of the KNBD study are as follows. In Korea, the DALY rate (per 100,000 people) steadily increased for all income levels. The higher the income, the lower the burden of disease; low-income people had a higher burden of disease than high-income people. However, thyroid cancer, refraction and accommodation disorders had a high burden of disease in the high-income group. Growth in the YLD rate was faster than in the YLL rate. In 2016 the leading causes of disease burden were diabetes mellitus, low back pain, and chronic obstructive pulmonary disease. We will present South Korea's disease burden calculation methodology and its results and share the efforts to calculate disease burden in other countries.

e16298 Background: The growing burden of obesity, type 2 diabetes, and metabolic risk factors has driven a rise in non-alcoholic steatohepatitis (NASH)-related liver cancer, surpassing HBV and HCV as major contributors. Despite advancements, the impact of NASH on cancer incidence and mortality, especially in the elderly, remains underexplored. Using the Global Burden of Diseases-2021 database, this study examines trends in DALYs, ASMRs, YLD, and YLL from 1990–2021 to address the rising global impact of NASH-related liver malignancies. Methods: Data from GBD 2021 were analyzed for 204 countries and territories from 1990 to 2021. Age-standardized mortality rates (ASMRs), disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs). Average annual percent changes (AAPC) were calculated by linear regression. Results: Globally, the ASMRs for liver malignancies due to NASH demonstrated a moderate overall increase, with an AAPC of +0.79 (95% CI: 0.71–0.87). Countries with the steepest increases included the United Kingdom (UK) (+4.42), Australia (+4.30), and Uruguay (+4.21). Conversely, regions such as the Republic of Korea (-2.58), Zambia (-2.76), and Bulgaria (-2.68) exhibited significant declines. The global DALYs and YLLs also showed an upward trend, with overall AAPCs of +0.53 (95% CI: 0.45–0.62) and +0.53 (95% CI: 0.44–0.61), respectively. The UK (DALY: +4.28, YLL: +4.26) and Poland (DALY: +4.25, YLL: +4.25) experienced the highest increases in both metrics, whereas Zambia (DALY: -3.21, YLL: -3.21) and the Republic of Korea (DALY: -3.00, YLL: -3.02) demonstrated significant reductions. In terms of YLD, a modest global increase was observed, with an AAPC of +1.09 (95% CI: 1.01–1.17). The sharpest increases were reported in the UK (+5.21) and Australia (+5.14), while Zambia (-2.89) and Bulgaria (-2.44) exhibited notable declines. Conclusions: While regions such as Zambia and the Republic of Korea showed consistent improvements across all metrics. The rising burden of NASH-related liver malignancies in the UK and Australia may stem from increasing obesity, sedentary lifestyles, high-fat diets, and aging populations. Healthcare disparities, delayed diagnoses, and urbanization could further drive these trends. Policies focusing on prevention, lifestyle changes, and equitable care are critical to mitigating this issue ASMRs, DALYs, YLLs and YLDs for global burden of liver malignancies due to NASH between 1990 and 2021. Outcome Global AAPC P-value Highest AAPC Lowest Burden Country AAPC (95% CI) Burden Country (95% CI) (95% CI) ASMRs 0.79 <0.001 UK 4.42 Zambia -2.76 (-0.71 to -0.87) (4.20 to 4.65) (-3.27 to -2.25) YLLs 0.52 <0.001 UK 4.26 Zambia -3.21 (0.44 to 0.61) (4.04 to 4.49) (-3.76 to -2.65) DALYs 0.53 <0.001 UK 4.27 Zambia -3.21 (0.45 to 0.61) (4.05-4.50) (-3.76 to -2.65) YLDs 1.09 <0.001 UK 5.21 Zambia -2.89 (1.01 to 1.17) (4.98 to 5.45) (-3.38 to -2.39)

Introducción. El trauma es reconocido como una epidemia global que varía según las regiones donde se presenta. Una parte de la carga de la enfermedad está determinada por los años perdidos de vida potencial, la cual es una estimación de amplio uso para la vigilancia en salud pública; sin embargo, existe poca información disponible en relación a esto. El objetivo de este estudio fue determinar la tendencia de los años perdidos de vida potencial por el trauma en un período de nueve años. Métodos. La información se obtuvo del Instituto Nacional de Medicina Legal y Ciencias Forenses en un período de nueve años (2007-2015). La población de referencia se determinó con base en las proyecciones del Departamento Administrativo Nacional de Estadística, que indicaron una expectativa de vida de 75 años. Resultados. En el 2015, a las lesiones por traumatismos en Colombia les correspondieron 1.920,7 años perdidos de vida potencial por cada 100.000 personas. Durante el período de estudio, las principales causas fueron los homicidios (rango, 51 a 68 %) y los accidentes de tránsito (rango, 19 a 28 %); la relación entre hombres y mujeres fue de 7:1, y la tendencia estadística fue hacia la disminución de los años perdidos de vida potencial. Conclusiones. Los homicidios siguen aportando el mayor número de lesiones por trauma y años perdidos de vida potencial. Los hombres jóvenes continuaron siendo la población mayormente afectada. Se conceptúa la necesidad de incrementar los esfuerzos para mejorar la vigilancia en salud pública y ahondar en las intervenciones oportunas relacionadas con el trauma.

e23508 Background: Bone and articular cartilage malignant neoplasms are rare, yet they contribute an important contribution to the overall morbidity and mortality brought about by cancer globally. Geographical and socioeconomic factors have been linked with variations in the disease burden of these cancers, which primarily impact the skeleton and joints. From 1990 to the year 2021, this study focuses on worldwide variations in the number of cases of cartilage and bone cancers. Methods: 204 different countries and territories' datasets from the Global Burden of Disease (GBD) 2021 study have been reviewed over a 31-year timeframe. Linear regression was used on the Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLLs), Age-Standardized Mortality Rates (ASMRs), and Years Lived with Disability (YLDs) to determine the Average Annual Percent Changes (AAPC). Results: The analysis revealed regional differences in the burden of bone and cartilage malignancies. The regions with the highest positive AAPC in ASMR included Saint Vincent and the Grenadines (3.59), China (3.27), and Puerto Rico (2.65). Conversely, countries with the steepest declines in ASMR included the Russian Federation (-4.51), Estonia (-3.75), and the Republic of Moldova (-3.60). The global ASMR for bone malignancies declined with an AAPC of -0.72%. For DALYs and YLLs, the global AAPC was -0.54% and -0.59%, respectively. Increases in DALYs and YLLs were observed in countries such as Guyana (DALY: 4.14, YLL: 4.11) and Zimbabwe (DALY: 3.11, YLL: 3.14). In contrast, declines were recorded in Norway (DALY: -5.42, YLL: -5.55) and Costa Rica (DALY: -2.48, YLL: -2.58). The trend in YLDs showed a global increase with an AAPC of +0.09%. The largest increases in YLDs were seen in Guyana (YLD: 4.74) and Mauritius (YLD: 3.54), while Norway (-4.40) and Saint Vincent and the Grenadines (-1.57) showed reductions. Conclusions: Despite the relatively small incidence rates, the global burden of bone diseases, as gauged by ASMR, DALY, and YLL, has steadily decreased in recent decades. Saint Vincent and the Grenadines, and China, identified among the increasing regions, may benefit from further investigation into the disease burden trends. Further studies should focus on identifying factors contributing to these changes. Outcome Global AAPC (95% CI) P-value Highest Increase AAPC (95% CI) Highest decline AAPC (95% CI) (Lowest) ASMRs -0.55 (-0.62 to -0.48) < 0.001 Saint Vincent and the Grenadines 3.59 (2.00 to 5.18) Russian Federation -4.51 (-5.10 to -3.92) DALYs -0.54 (-0.59 to -0.49) <0.0001 Saint Vincent and the Grenadines 4.23 (2.44 to 5.87) Estonia -3.65 (-4.12 to -3.18) YLLs -0.59 (-0.64 to -0.53) <0.0001 Saint Vincent and the Grenadines 4.11 (2.41 to 5.84) Russian Federation -5.55 (-5.96 to -5.14) YLDs 0.09 (0.04 to 0.14) 0.001 Saint Vincent and the Grenadines -1.57 (-2.10 to -0.50) Norway -4.40 (-4.87 to -3.93)

BackgroundExamining the distribution of the burden of different communicable and non-communicable diseases and injuries worldwide can present proper evidence to global policymakers to deal with health inequality. The present study aimed to determine socioeconomic inequality in the burden of 25 groups of diseases between countries around the world in 2019.MethodsIn the current study data according to 204 countries in the world was gathered from the Human Development Report and the Global Burden of Diseases study. Variables referring to incidence, prevalence, years of life lost (YLL), years lived with disability (YLD) and disability adjusted life years (DALY) resulting by 25 groups of diseases and injuries also human development index was applied for the analysis. For measurement of socioeconomic inequality, concentration index (CI) and curve was applied. CI is considered as one of the popular measures for inequality measurement. It ranges from − 1 to + 1. A positive value implies that a variable is concentrated among the higher socioeconomic status population and vice versa.ResultsThe findings showed that CI of the incidence, prevalence, YLL, YLD and DALY for all causes were − 0.0255, − 0.0035, − 0.1773, 0.0718 and − 0.0973, respectively. CI for total Communicable, Maternal, Neonatal, and Nutritional Diseases (CMNNDs) incidence, prevalence, YLL, YLD and DALY were estimated as − 0.0495, − 0.1355, − 0.5585, − 0.2801 and − 0.5203, respectively. Moreover, estimates indicated that CIs of incidence, prevalence, YLL, YLD and DALY for Non-Communicable Diseases (NCDs) were 0.1488, 0.1218, 0.1552, 0.1847 and 0.1669, respectively. Regarding injuries, the CIs of incidence, prevalence, YLL, YLD and DALY were determined as 0.0212, 0.1364, − 0.1605, 0.1146 and 0.3316, respectively. In the CMNNDs group, highest and lowest CI of DALY were related to the respiratory infections and tuberculosis (− 0.4291) and neglected tropical diseases and malaria (− 0.6872). Regarding NCDs, the highest and lowest CI for DALY is determined for neoplasms (0.3192) and other NCDs (− 0.0784). Moreover, the maximum and minimum of CI of DALY for injuries group were related to the transport injuries (0.0421) and unintentional injuries (− 0.0297).ConclusionsThe distribution of all-causes and CMNNDs burden were more concentrated in low-HDI countries and there are pro-poor inequality. However, there is a pro-rich inequality for NCDs’ burden i.e. it was concentrated in high-HDI countries. On the other hand, the concentration of DALY, YLD, prevalence, and incidence in injuries was observed in the countries with higher HDI, while YLL was concentrated in low-HDI countries.

BackgroundThe Disability Adjusted Life Year (DALY) is a measure to prioritize in the public health field. In the Netherlands, the DALY estimates are calculated since 1997 and are included in the Public Health Status and Foresight studies which is an input for public health priority setting and policy making. Over these 20 years, methodological advancements have been made, including accounting for multimorbidity and performing projections for DALYs into the future. Most important methodological choices and improvements are described and results are presented.MethodsThe DALY is composed of the two components years of life lost (YLL) due to premature mortality and years lost due to disability (YLD). Both the YLL and the YLD are distinguished by sex, age and health condition, allowing aggregation to the ICD-10 chapters. The YLD is corrected for multimorbidity, assuming independent occurrence of health conditions and a multiplicative method for the calculation of combined disability weights. Future DALYs are calculated based on projections for causes of death, and prevalence and incidence.ResultsThe results for 2015 show that cancer is the ICD-10 chapter with the highest disease burden, followed by cardiovascular diseases and mental disorders. For the individual health conditions, coronary heart disease had the highest disease burden in 2015. In 2040, we see a strong increase in disease burden of dementia and arthrosis. For dementia this is due to a threefold increase in dementia as a cause of death, while for arthrosis this is mainly due to the increase in prevalence.ConclusionsTo calculate the DALY requires a substantial amount of data, methodological choices, interpretation and presentation of results, and the personnel capacity to carry out all these tasks. However, doing a National Burden of Disease study, and especially doing that for more than 20 years, proved to have an enormous additional value in population health information and thus supports better public health policies.

Disability Adjusted Life-Years (DALYs) As a Measure of the Changing Lifetime Disease Burden in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT)